Study Demonstrating Pancreatic Islet Xenograft Survival With Kamada's AAT

Kamada Ltd. (Nasdaq and TASE: KMDA) have announced that favorable results from a preclinical study analyzing the effects of the Company's human Alpha-1 Antitrypsin (AAT), Glassia, in inter-species islet graft transplantation were published in PLOS One, an open-access peer-reviewed publication. The article is entitled "Pancreatic Islet Xenograft Survival in Mice Is Extended by a Combination of Alpha-1-Antitrypsin and Single Dose Anti-CD4/CD8 Therapy." The study was funded by the Juvenile Diabetes Research Foundation and performed by the team of Eli C. Lewis, Ph.D...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Transplants / Organ Donations Source Type: news